Loading…
Jilin TCM and investment holding group best known for its large minority stake in insulin maker Tonghua Dongbao.
Jilin TCM and investment holding group best known for its large minority stake in insulin maker Tonghua Dongbao.
Its reported profit blends its own traditional-medicine sales with investment income from the stake in Tonghua Dongbao, an insulin maker, booked as earnings from an associate. Results therefore follow insulin sales as much as the group's own products.
In one line: A Chinese TCM maker that is also a holding-company stakeholder.
Moat: narrow (brand). Own TCM brands plus investment value tied to its stake in an insulin maker, not a single operating moat.
Headquarters: Dunhua, Jilin, China · Employees: 5,461
Size Jilin Aodong Pharmaceutical (000623.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $3.02B, the 851st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥17.20 on 6 Nov 2026.
Performance Over six months the shares fell 8.8%, against -1.5% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 4.4% over the last twelve months (peer median +9.1%); the operating margin is -13.0% (peer median 16.4%).
Valuation It trades at 8.6× enterprise value to sales against a peer median of 3.4× (3rd most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.5 points below its cost of capital (8.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.24B | CN¥2.32B | CN¥2.60B | CN¥3.40B | CN¥2.83B |
| Revenue growth | — | -11% | -24% | +20% | — |
| Gross profit | CN¥1.18B | CN¥1.03B | CN¥946M | CN¥1.59B | CN¥1.37B |
| EBITDA | n/a | CN¥58.4M | CN¥99.5M | CN¥364M | CN¥344M |
| Net income | CN¥2.99B | CN¥2.40B | CN¥1.55B | CN¥1.46B | CN¥1.78B |
| Free cash flow | CN¥1.10B | CN¥864M | CN¥493M | CN¥273M | CN¥982M |
| Capital expenditure | CN¥101M | CN¥128M | CN¥274M | CN¥420M | CN¥271M |
| Total debt | CN¥2.10B | CN¥2.25B | CN¥2.30B | CN¥3.04B | CN¥3.00B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Jilin Aodong Pharmaceutical 000623.SZ | $3.02B | -9% | -4% | -13% | 8.6× | 5.2% |
| Tonghua Dongbao Pharmaceutical 600867.SS | $2.29B | -14% | +18% | n/a | 4.4× | 1.6% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 1.9× | -6.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000623.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.3% | +2.9% | 7th lowest of 21 |
| 6-month return | -8.8% | -1.5% | 6th lowest of 21 |
| Distance from 52-week high | -22.1% | -17.7% | 8th lowest of 21 |
| Revenue growth (TTM) | -4.4% | +9.1% | 6th lowest of 21 |
| Operating margin | -13.0% | 16.4% | lowest of 21 |
| EV / Sales | 8.6× | 3.4× | 3rd most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 5.2% | -0.8% | 6th most demanding of 20 |
| Growth delivered (Del g) | +1.0% | +5.9% | 5th lowest of 20 |
| Hurdle (Req g minus delivered) | +4.2 pp | -7.7 pp | 5th most demanding of 20 |
| ROIC minus cost of capital | -8.5 pp | +4.1 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jilin Aodong Pharmaceutical 000623.SZ | China | $3.02B | -9% | -4% | -13% | 8.6× | 5.2% | +1.0% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 2.0× | -14.5% | +5.9% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 9.3× | 34.7% | +5.9% |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 2.0× | 5.1% | +0.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 1.6× | -8.3% | +5.3% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $4.02B | -6% | +32% | 21% | 3.1× | -3.2% | -2.2% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 3.9× | -2.5% | +11.6% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 3.3× | 23.5% | +10.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 1.3× | -3.0% | +4.4% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | 0.6× | -0.8% | -2.1% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | 3.6× | 5.3% | +10.4% |
| Dong-E-E-Jiao 000423.SZ | China | $4.80B | -8% | +8% | 29% | 3.6× | -4.6% | +14.5% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | 4.2× | -1.1% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 1.0× | -6.7% | +3.9% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 3.4× | 4.5% | +60.2% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 4.4× | -2.2% | +5.5% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 18.9× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 2.7× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 3.3× | 2.1% | +26.7% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 4.4× | 11.4% | -3.9% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 7.2× | 0.9% | +15.5% |